Icahn buys into Genzyme
690464
Carl Icahn, the billionaire investor who recently helped put Biogen Idec Inc. in play, has taken a stake in another major Cambridge biotech - Genzyme Corp.
62500
Genzyme Corp. won approval Wednesday for a childhood leukemia drug under an accelerated government approval process for potentially lifesaving treatments.
456207
Dutch chemical group Akzo Nobel NV   said on Monday it is selling its  pharmaceutical unit Organon BioSciences to Schering-Plough   for 11 billion euros ($14.5 billion).
238851
Genzyme Corp.  said on Friday  its osteoarthritis pain treatment Synvisc will retain a  separate, higher reimbursement rate, after the U.S. government  reversed its earlier decision to cut the rate, sending Genzyme  shares higher.
356950
Consolidation in Europe's drugs   sector gathered steam on Thursday as Germany's Merck unveiled a   $13.3-billion deal to buy Europe's top biotech firm Serono, and   Denmark's Nycomed won the drugs unit of Altana.
382580
Genzyme Corp. of Cambridge, Mass., agreed Thursday to buy back the sales and marketing rights for Synvisc, a pain treatment for people suffering from osteoarthritis of the knee, from Wyeth Pharmaceuticals of Collegeville, Pa.
753120
Carl Icahn, the billionaire investor who took over TWA in the 1980s and has battled executives at Motorola , Time Warner , and other iconic corporations, now appears to have Biogen Idec Inc. in his crosshairs.
337666
SAN FRANCISCO -- Billionaire investor Carl C. Icahn was given clearance by US antitrust regulators to purchase shares in Biogen Idec Inc., the world's biggest maker of drugs for multiple sclerosis.
531882
FRANKFURT/ZURICH  - Germany drugmaker Merck KGaA   MRCG.DE unveiled a surprise 16.6-billion-Swiss franc ($13.3   billion) deal on Thursday to buy Swiss biotech firm Serono,   creating a new force in European pharmaceuticals.
572919
Biotech titan Genzyme (Nasdaq: GENZ) has its roots in the treatment of rare genetic diseases and also has a significant presence in the treatment of renal diseases and providing diagnostic testing services.
599973
Investor Carl Icahn issued a $20-per-share bid to acquire Mylan Laboratories Inc. on Friday and said &quot;at least&quot; three other potential buyers in the generic drug industry could offer more.
412704
NEW YORK (CBS.MW) -- The Food and Drug Administration has approved Genzyme Corp. and Bioenvision Inc.&#39;s treatment for the most common type of childhood leukemia, sending shares of both companies higher Wednesday.
131156
LONDON (CBS.MW) -- The US Food and Drug Administration has approved a Genzyme Corp. (GENZ) cancer drug for treating a type of childhood leukemia after other therapies have failed.
643395
Genzyme Corp. hasn't given up on plans to buy Bioenvision Inc., one of its most important partners, despite mounting shareholder complaints that Genzyme's offer is too low.
757229
Genzyme Corp. of Cambridge and German partner Bayer Schering Pharma AG said they have begun phase 3 trials of their cancer drug Campath to treat multiple sclerosis. The companies said they plan on reporting phase 2 results Oct. 14. After phase 3, they hope to seek US regulatory approval in 2011 to market the drug, also known as alemtuzumab, to ...
28028
Genzyme Corp.&#39;s not-yet-completed $1 billion acquisition of Ilex Oncology Inc. appeared to pay off yesterday when an advisory committee to the Food and Drug
246930
Biotechnology company Genzyme Corp  reported a fourth-quarter profit on Wednesday, reversing a year-earlier loss, as sales of its drugs for rare diseases increased.